• Search History (Register)
  • MeSH Browser
Sort by Relevance
Search Results [223 Hits] Selected Records [0 Hits] [Clear]
Year Source Title
2025 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bulevirtide (chronic hepatitis D, children >= 3 to < 18 years, >= 10 kg) – assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024 Health Information and Quality Authority (HIQA) Health technology assessment of birth cohort testing for hepatitis C: a short report update
2023 Canadian Agency for Drugs and Technologies in Health (CADTH) Direct-acting antivirals for pediatric chronic hepatitis C virus infection
2023 National Institute for Health and Care Excellence (NICE) Bulevirtide for treating chronic hepatitis D. NICE technology appraisal guidance 896
2022 NIHR Health Technology Assessment programme Telaprevir for the treatment of genotype 1 chronic hepatitis C
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sofosbuvir/ velpatasvir/ voxilaprevir (hepatitis C, 12 to adolescents)
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elbasvir/grazoprevir (chronic hepatitis C in adolescents) - Benefit assessment according to §35a Social Code Book V]
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sofosbuvir/velpatasvir (chronic hepatitis C in children 3 to < 6 years of age) - Benefit assessment according to §35a Social Code Book V]
2022 Andalusian Health Technology Assessment Area (AETSA) [Clinical effectiveness, safety, and economic assessment of mass screening for hepatitis C. Systematic review]
2021 Health Information and Quality Authority (HIQA) Health technology assessment of birth cohort testing for hepatitis C
2021 The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Bulevirtide (chronic hepatitis delta virus (HDV) infection)]
2021 Agency for Care Effectiveness (ACE) Tenofovir alafenamide for treating chronic hepatitis B infection
2021 Center for Drug Evaluation (CDE) Effects of direct-acting antiviral therapy for patients with advanced hepatocellular carcinoma and concomitant hepatitis C-A population-based cohort study
2021 The National Health Care Institute (ZIN, Zorginstituut Nederland) Advice on the clustering of combination products and ghost clusters in GVS
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Glecaprevir/pibrentasvir (chronic hepatitis C in children) - Benefit assessment according to §35a Social Code Book V]
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Glecaprevir/pibrentasvir (chronic hepatitis C in children) - Benefit assessment according to §35a Social Code Book V]
2020 Malaysian Health Technology Assessment (MaHTAS) Hepatitis C virus screening and surveillance tests for dialysis patients
2020 Malaysian Health Technology Assessment (MaHTAS) Strategies to eliminate mother to child transmission of hepatitis B in Malaysia
2020 Canary Health Service [Cost-effectiveness of universal childhood vaccination against hepatitis A (update)]
2020 Agency for Care Effectiveness (ACE) Direct-acting antiviral agents for treating genotype 1 chronic hepatitis C
2020 Agency for Care Effectiveness (ACE) Direct-acting antiviral agents for treating genotype 2 to 6 chronic hepatitis C
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ledipasvir/sofosbuvir (chronic hepatitis C in children) - Benefit assessment according to §35a Social Code Book V]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sofosbuvir (chronic hepatitis C in children) - Benefit assessment according to §35a Social Code Book V]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bulevirtide (chronic hepatitis delta virus infection) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sofosbuvir/velpatasvir (chronic hepatitis C in children and adolescents) - Benefit assessment according to §35a Social Code Book V]
2019 Institute for Clinical Effectiveness and Health Policy (IECS) [Shear-wave elastography for liver fibrosis]
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Glecaprevir/pibrentasvir (chronic hepatitis C in adolescents) - Benefit assessment according to §35a Social Code Book V]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sofosbuvir (hepatitis C in adolescents) - Benefit assessment according to §35a Social Code Book V]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sofosbuvir/velpatasvir/voxilaprevir (chronic hepatitis C) - Addendum to Commission A17-35]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Screening for hepatitis B]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Screening for hepatitis C]
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tenofovir alafenamide (chronic hepatits B) - Benefit assessment according to §35a Social Code Book V]
2018 National Institute for Health and Care Excellence (NICE) Glecaprevir–pibrentasvir for treating chronic hepatitis C. NICE technology appraisal guidance 499
2018 National Institute for Health and Care Excellence (NICE) Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C. NICE technology appraisal guidance 507
2017 NIHR Public Health Research (PHR) programme Assessing the impact and cost-effectiveness of needle/syringe provision and opiate substitution therapy on hepatitis C transmission among people who inject drugs in the United Kingdom: analysis of pooled datasets and economic modelling
2017 HAYES, Inc. Zepatier (Grazoprevir and Elbasvir) for chronic hepatitis C infection
2017 Andalusian Health Technology Assessment Area (AETSA) Direct acting antivirals for the chronic hepatitis C infection. Relative assessment of efficacy and safety. Executive summary
2017 Canadian Agency for Drugs and Technologies in Health (CADTH) Screening for hepatitis C virus: a systematic review
2017 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elbasvir/grazoprevir (chronic hepatitis C): Benefit assessment according to §35a Social Code Book V]
2017 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tenofovir alafenamide (chronic hepatitis B) - Benefit assessment according to §35a Social Code Book V]
2017 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Glecaprevir/pibrentasvir (chronic hepatitis C) - Benefit assessment according to § 35a Social Code Book V]
2017 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sofosbuvir/velpatasvir/voxilaprevir (chronic hepatitis C) - Benefit assessment according to §35a Social Code Book V]
2017 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ledipasvir/sofosbuvir (hepatitis C) - Benefit assessment according to §35a Social Code Book V]
2017 National Institute for Health and Care Excellence (NICE) Sofosbuvir-velpatasvir for treating chronic hepatitis C. NICE technology appraisal guidance 430
2017 National Institute for Health and Care Excellence (NICE) Tenofovir alafenamide for treating chronic hepatitis B (terminated appraisal). NICE technology appraisal guidance 435
2016 NIHR Horizon Scanning Centre (NIHR HSC) Glecaprevir with pibrentasvir for chronic hepatitis C infection, genotypes 1, 2, 3, 4, 5 and 6
2016 NIHR Horizon Scanning Centre (NIHR HSC) Sofosbuvir, GS-9857 and velpatasvir triple therapy for chronic hepatitis C
2016 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Hepatitis C virus screening in hospitals]
2016 Belgian Health Care Knowledge Centre (KCE) Economic evaluation of novel direct acting antiviral (DAA) treatment strategies for chronic hepatitis C
2016 HAYES, Inc. Sofosbuvir-velpatasvir for chronic HCV infection
2016 Adelaide Health Technology Assessment (AHTA) Enhanced liver fibrosis test
2016 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sofosbuvir/velpatasvir (chronic hepatitis C) - Benefit assessment according to §35a SGB V]
2016 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sofosbuvir/velpatasvir (chronic hepatitis C) - Addendum to Commission A16-48]
2016 National Institute for Health and Care Excellence (NICE) Elbasvirgrazoprevir for treating chronic hepatitis C. NICE technology appraisal guidance 413
2015 NIHR Horizon Scanning Centre (NIHR HSC) Asunaprevir, beclabuvir and daclatasvir fixed dose combination for hepatitis C virus infection, genotype 1 – first or second line
2015 NIHR Horizon Scanning Centre (NIHR HSC) Sofosbuvir (Sovaldi) with GS-5816 for chronic hepatitis C
2015 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Entecavir (Baraclude®)
2015 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Daclatasvir (Daklinza®)
2015 NIHR Health Technology Assessment programme Ledipasvir-sofosbuvir for treating chronic hepatitis C [ID742]
2015 NIHR Health Technology Assessment programme Ombitasvir/paritaprevir/ritonavir with or without dasabuvir for treating chronic hepatitis C
2015 NIHR Health Technology Assessment programme Daclatasvir for treating chronic hepatitis C
2015 Institute for Clinical Effectiveness and Health Policy (IECS) [Assessment on nucleic acid amplification techniques (NAT) for human immunodeficiency, hepatitis C and hepatitis B virus screening in blood banks]
2015 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Ledipasvir/sofosbuvir (Harvoni®)
2015 HAYES, Inc. Second-wave direct-acting antivirals for hepatitis C: ledipasvir-sofosbuvir
2015 HAYES, Inc. Second-wave direct-acting antivirals for hepatitis C: sofosbuvir
2015 Institute for Clinical Effectiveness and Health Policy (IECS) [Sofosbuvir and simeprevir-based schemes for the management of hepatitis C]
2015 Institute for Clinical Effectiveness and Health Policy (IECS) [Ombitasvir, paritaprevir and ritonavir regimens in hepatitis C patients]
2015 HAYES, Inc. Second-wave direct-acting antivirals for hepatitis C: Simeprevir
2015 Canadian Agency for Drugs and Technologies in Health (CADTH) Holkira (ombitasvir/paritaprevir/ ritonavir with dasabuvir) and Harvoni (ledipasvir/sofosbuvir) for chronic hepatitis C: a review of the clinical evidence
2015 NIHR Horizon Scanning Centre (NIHR HSC) Simeprevir in combination with sofosbuvir (with or without ribavirin) for chronic hepatitis C
2015 NIHR Horizon Scanning Centre (NIHR HSC) Tenofovir alafenamide monotherapy for hepatitis B
2015 Andalusian Health Technology Assessment Area (AETSA) [Selection criteria for direct antiviral agents for patients with chronic hepatitis c in the SSPA]
2015 Andalusian Health Technology Assessment Area (AETSA) [Simeprevir in the treatment of chronic hepatitis C. Comparative efficacy and safety assessment]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A14-31 (daclatasvir)]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ledipasvir/sofosbuvir - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dasabuvir - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ombitasvir/paritaprevir/ritonavir - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ledipasvir/sofosbuvir (Addendum to Commission A14-44)]
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dasabuvir/ombitasvir/paritaprevir/ritonavir (Addendum to Commissions A15-03 and A15-04)]
2015 National Institute for Health and Care Excellence (NICE) Sofosbuvir for treating chronic hepatitis C. NICE technology appraisal guidance 330
2015 National Institute for Health and Care Excellence (NICE) Ledipasvir-sofosbuvir for treating chronic hepatitis C. NICE technology appraisal guidance 363
2015 National Institute for Health and Care Excellence (NICE) Ombitasvir-paritaprevir-ritonavir with or without dasabuvir for treating chronic hepatitis C. NICE technology appraisal guidance 365
2015 National Institute for Health and Care Excellence (NICE) Virtual Touch Quantification to diagnose and monitor liver fibrosis in chronic hepatitis B and C. NICE medical technologies guidance 27
2014 NIHR Health Technology Assessment programme The clinical effectiveness and cost-effectiveness of peginterferon alfa and ribavirin for the treatment of chronic hepatitis C in children and young people: a systematic review and economic evaluation
2014 NIHR Health Technology Assessment programme Sofosbuvir for treating chronic hepatitis C
2014 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Tenofovir disoproxil fumarate (Viread®)
2014 NIHR Horizon Scanning Centre (NIHR HSC) Daclatasvir and sofosbuvir (Sovaldi) with and without ribavirin for chronic hepatitis C infection
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Direct acting antivirals for chronic hepatitis C genotype 1 in select populations: emerging evidence of clinical effectiveness and safety
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Re-treatment with direct acting antivirals for chronic hepatitis C genotype 1: emerging evidence of clinical effectiveness and safety
2014 NIHR Horizon Scanning Centre (NIHR HSC) MK-5172 and MK-8742 fixed dose combination for chronic hepatitis C infection (genotypes 1, 4, 5 and 6)
2014 NIHR Horizon Scanning Centre (NIHR HSC) Peginterferon lambda-1a for hepatitis C
2014 HAYES, Inc. Second-wave direct-acting antivirals for hepatitis C: Simeprevir
2014 HAYES, Inc. Second-wave direct-acting antivirals for hepatitis C: Sofosbuvir and Ledipasvir
2014 Institut national d'excellence en sante et en services sociaux (INESSS) [Profile of individuals insured by the public prescription drug insurance plan who have received treatment for hepatitis C (HCV)]
2014 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Eltrombopag (Revolade®)
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Pharmacoeconomic review report. Sofosbuvir (Sovaldi — Gilead Sciences Canada, Inc.) indication: chronic hepatitis C infection
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Simeprevir (Galexos — Janssen Inc.) indication: chronic hepatitis C genotype 1 infection
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Interferon-free regimens for chronic hepatitis C genotype 1
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Interferon-free regimens for genotype 1 chronic hepatitis C: a review of the clinical evidence and cost-effectiveness
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Treatments for patients with genotype 1 chronic hepatitis C: a review of evidence-based guidelines